What Is the First-Line Treatment for Osteoporosis with Pathological Fracture?
Osteoporosis with pathological fracture (ICD-10 M80 / ICD-11 FB80.B/FB83.1) is a high-fracture-risk condition requiring a structured, evidence-based approach combining pharmacological therapy, nutritional optimisation, and supervised exercise. This page summarises the key elements of first-line management — the complete protocol is accessible via the link below.
Treatment Approach
First-line management centres on bisphosphonate therapy, available in oral and intravenous formulations, with selection guided by individual patient factors. Nutritional support and a structured weight-bearing exercise programme form integral components of the regimen.
The specific agents, treatment duration thresholds, supplemental protocol, and patient-specific criteria are fully defined in the linked regimen — only a partial overview is provided here.
Clinical Goals
Success is measured by meaningful improvement in hip and lumbar spine bone mineral density T-scores over three years, adequate suppression of bone turnover markers at three to six months, and maintenance of a sufficient serum vitamin D concentration. Specific numeric targets and monitoring intervals are detailed in the full protocol.
References
DOI: 10.1136/bmj‑2024-081250
- For patients at high risk, AACE, Endocrine Society, BHOF, and NOGG recommend alendronate, risedronate, or zoledronate as first line therapy.
- For postmenopausal women and older men, aim for total elemental calcium 1000-1200 mg/day and vitamin D 800-1000 IU/day.
- Osteoporosis and sarcopenia guidelines both stress the need for regular weight bearing, resistance, and balance training exercise for reducing the risk of falls and fractures.
- In patients with low T-scores, a target of T ≥−2.5 is generally adopted as an appropriate threshold for discontinuation of therapy, on the basis of the FLEX and HORIZON-PFT trials, and endorsed by the latest American Society of Bone and Mineral Research guidance on goal directed osteoporosis treatment.
- Experts recommend an improvement in total hip T-score of at least 0.2 units (3%) and in lumbar spine T-score of at least 0.5 units (6%), on the basis of reasonable chances of attaining such increments over three years by most therapies, including anti-resorptives.
- The National Academy of Medicine recommends a target 25-hydroxyvitamin D concentration of 20 ng/mL, whereas other guidelines suggest 30 ng/mL for older adults and at-risk populations.